3 results
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…
(protocol section 2) This phase 1 study aims to assess the safety and tolerability of monoclonal antibody TB31F administered intravenously or at escalating dose levels or subcutaneously in healthy, malaria naïve, adults. This study will also…